Verity Asset Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Verity Asset Management’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-12,246	Closed	-$122K	–	165
2017 Q3	$122K	Sell	12,246 -1,658	-12%	-$18.6K	0.09%	116
2017 Q2	$146K	Buy	+13,904	New	+$142K	0.11%	113

Other funds holding SCMP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Verity Asset Management's SCMP Position: Q4 2017 in Review

Verity Asset Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2017, closing a stake of 12,246 shares — an estimated $122K sold.

Verity Asset Management first reported a position in SCMP in Q2 2017 and held it in 2 quarters. The position peaked at $146K in Q2 2017. 188 funds tracked by Wall St. Rank hold SCMP as of Q4 2017.

Verity Asset Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Verity Asset Management sold 12,246 Sucampo Pharmaceuticals, Inc. shares in Q4 2017, an estimated $122K.
Verity Asset Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2017 and held it in 2 quarters.
Verity Asset Management's Sucampo Pharmaceuticals, Inc. position peaked at $146K in Q2 2017.
188 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2017.

Based on Verity Asset Management's 13F filing for Q4 2017, filed 7 Feb 2018.